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Summary
Objective: Pathogenic variants in SCN8A have been associated with a wide spectrum 
of epilepsy phenotypes, ranging from benign familial infantile seizures (BFIS) to epi-
leptic encephalopathies with variable severity. Furthermore, a few patients with intel-
lectual disability (ID) or movement disorders without epilepsy have been reported. 
The vast majority of the published SCN8A patients suffer from severe developmental 
and epileptic encephalopathy (DEE). In this study, we aimed to provide further in-
sight on the spectrum of milder SCN8A- related epilepsies.
Methods: A cohort of 1095 patients were screened using a next generation sequenc-
ing panel. Further patients were ascertained from a network of epilepsy genetics clin-
ics. Patients with severe DEE and BFIS were excluded from the study.
Results: We found 36 probands who presented with an SCN8A- related epilepsy and 
normal intellect (33%) or mild (61%) to moderate ID (6%). All patients presented 
with epilepsy between age 1.5 months and 7 years (mean = 13.6 months), and 58% of 
these became seizure- free, two- thirds on monotherapy. Neurological disturbances in-
cluded ataxia (28%) and hypotonia (19%) as the most prominent features. Interictal 
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1 |  INTRODUCTION
SCN8A encodes the voltage- gated sodium channel Nav1.6, 
which is primarily expressed in excitatory neurons with 
high concentrations at the axon initial segment and the 
node of Ranvier. Pathogenic variants in SCN8A are associ-
ated with a spectrum of epilepsy phenotypes, ranging from 
rare families with benign familial infantile seizures (BFIS) 
to severe early onset developmental and epileptic encepha-
lopathies (DEE; EIEE13, Online Mendelian Inheritance in 
Man database #614558). Since the first case report pub-
lished by Veeramah and colleagues in 2012,1 several reports 
have confirmed the role of SCN8A, primarily in patients 
with DEE.2–9 The majority of patients with SCN8A DEE 
described so far have a severe phenotype characterized by 
early seizure onset, difficult to treat seizures, severe intel-
lectual disability (ID), motor disorders, and a relatively high 
mortality.2–10
Functional studies of selected variants causing DEE have 
revealed gain of function (GOF) as the main pathogenic 
mechanism.1,6,11,12 This GOF comes from hyperactivity of 
the ion channel, due to elevated persistent sodium currents, 
hyperpolarizing shifts in the voltage dependence of activa-
tion, or impaired channel current inactivation.12,13 This mech-
anism is the opposite of the one that has been demonstrated in 
Dravet syndrome, which is characterized by loss- of- function 
(LOF) variants in SCN1A.14 SCN1A encodes the voltage- 
gated sodium channel Nav1.1, which is primarily expressed 
in inhibitory interneurons. Variants in SCN2A, encoding a 
third voltage- gated sodium channel in the human central ner-
vous system, can lead to both GOF and LOF, complicating 
things even more.15 Awareness of these important differences 
in pathophysiology is necessary, as it might have therapeutic 
implications.16
We have recently detected a recurrent SCN8A variant, 
Glu1483Lys, in a very mild familial epilepsy phenotype.17 
We identified three unrelated families with a total of 16 fam-
ily members who presented with BFIS and normal cognition. 
Five family members developed paroxysmal kinesigenic dys-
kinesia.17 Recently, Han et al confirmed BFIS as part of the 
phenotypic spectrum in SCN8A- related epilepsies.18 In addi-
tion to these two extreme phenotypes, there are an increasing 
number of patients with a milder form of DEE. In this study, 
we describe the spectrum of the electroclinical features of 
this intermediate SCN8A epilepsy phenotype, aiming to pro-
vide a clearer picture for clinicians, genetic counselors, and 
affected families.
2 |  MATERIALS AND METHODS
We systematically screened all exons and exon- intron bound-
aries of SCN8A in a cohort of 1095 unselected patients with 
various forms of epilepsy using different next generation se-
quencing (NGS) panels.19 The panels included from 45 to 
500+ genes related to epilepsy, intellectual disability, or au-
tism. Variants were assumed to be pathogenic if they arose de 
novo, or were inherited from an affected parent or affected/
unaffected mosaic parent, and if they were nonsynonymous, 
splice- site altering, or frameshift causing, and not present 
in controls in the gnomAD browser (see Web Resources). 
Sanger sequencing confirmed variants and segregation. 
Furthermore, detected variants were tested (PolyPhen- 2, 
SIFT, and MutationTaster) for predicted pathogenicity. 
American College of Medical Genetics and Genomics 
(ACMG) and Missense badness, PolyPhen- 2, and Constraint 
(MPC) scores are noted in Table 1. All variants, except for 
one, were either pathogenic or likely pathogenic according to 
the ACMG criteria.20
Four different metrics were used for in silico variant 
pathogenicity prediction:
electroencephalogram was normal in 41%. Several recurrent variants were observed, 
including Ile763Val, Val891Met, Gly1475Arg, Gly1483Lys, Phe1588Leu, 
Arg1617Gln, Ala1650Val/Thr, Arg1872Gln, and Asn1877Ser.
Significance: With this study, we explore the electroclinical features of an interme-
diate SCN8A- related epilepsy with mild cognitive impairment, which is for the ma-
jority a treatable epilepsy.
K E Y W O R D S
epilepsy, epilepsy genetics, intellectual disability, SCN8A, voltage-gated sodium channels
Key Points
• The phenotypic spectrum of SCN8A is wide, from 
BFIS to DEE
• The intermediate phenotype is characterized by a 
treatable epilepsy and mild cognitive delay
• Prognostic markers remain elusive
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T A B L E  1  Clinical characteristics of the probands
Proband #
Age at 
inclusion Variant, inheritance, location
Pathogenicity per ACMG 
guidelines, MPC Family history Age at SZ onset SZ types
Interictal EEG/ictal 
EEG
Cognition before SZ 
onset/cognition after SZ 
onset Treatment response
Successful 
monotherapy Other features
1 2 y 8 mo c.- 8A>G de novo 5’UTR Pathogenic None 11 mo GTC, AA EDs on the P- temporal 
regions bilaterally, with 
rare diffuse spreading
N/MID SZ reduction: VPA 50% Hypotonia, uncoordinated 
movements, gait disturbance
2 9 y c.411C>G p.Ile137Met maternal 
transmembrane domain D1S1
Likely pathogenic (PM1, PM2, 
PP1, PP2, PP3) 
MPC = 1.66
Mother, at 10- 11 y: episodes of 
loss of balance, lower limb 
hyposthenia and falls, gait 
disturbance and hand tremor 
2 y 2 mo Staring/hypotonia to 
GTC, A, F (visual)
Temporal- O spikes/SW 
(left side predominance)
MID/MID SZ reduction: LTG, VPA, ZNS; 
no effect: LEV, RFM, TPM
Hypotonia, hypothyroidism 
enuresis, sleep disorders
3 9 y 4 mo c.1122C>G p.Asn374Lys de novo 
pore- forming domain
Likely pathogenic (PS2, PP2, PP3) 
MPC = 1.83
Maternal cousin with SZ 7 y Nocturnal frontal, T, 
GTC, SE
Multifocal SW, 
paroxysmal beta activity 
that lasts 1- 2 min
N/MID SZ- free: PHT, VPA; 
no effect: OXC, LEV, ZNS, 
CLB
Gait disturbance
4 c.1630_1631del p.Asn544 fs*39 
maternal cytoplasmic domain D1/D2
Pathogenic (PVS1, PM2, PP1) See Figure 1 2 y 9 mo Ab Slow wave and SW 
discharges
N/MID SZ- free: VPA + ESM + AMD; 
SZ reduction: VPA + ESM
5 13 y 2287A>G p.Ile763Val de novo 
transmembrane domain D2S1
Pathogenic (PS1, PS2, PM1, PM2, 
PP2) 
MPC = 1.51
Cousin with febrile SZ 7 wk GTC NA NA/MID SZ- free: CLB, ZNS, PHT, LTG, 
CBZ; 
adverse effects: LEV 
(behavior), CLZ, and LZP 
(sleepiness)
Hypotonia, ataxia, chronic 
constipation, premature 
adrenarche, periodic leg 
movement
6 20 y c.2287A>G p.Ile763Val de novo 
transmembrane domain D2S1
Pathogenic (PS1, PS2, PM1, PM2, 
PP2) MPC = 1.51
None 3 mo S, F EDs, both hemispheres; 
ictal: right F- temporal 
onset, then rhythmic 
slow activity 
propagating into the 
right parasagittal regions
NA/MID No effect: VPA, CBZ, LTG, 
CLB, acetazolamide
Ataxia
7 11 y c.2671G>A p.Val891Met maternal 
transmembrane domain D2S5
Pathogenic (PS1, PM1, PM2, PP1, 
PP2) 
MPC = 3.14
See Figure 1 3 y GTC, AA CP and midline spikes N/MID SZ- free: CBZ CBZ ADHD
8 10 y c.2806G>A p.Glu936Lys nonmaternal 
pore- forming domain
Likely pathogenic (PM1, PM2, 
PP1, PP2) 
MPC = 3.33
Father with ID and ADHD 5 y F, AA, FS SW left F, C, right P NA/MD SZ- free: LEV; 
adverse effects: TPM
LEV Autistic features, behavioral 
problems
9 9 y 9 mo c.3601G>A p.Glu1201Lys de novo 
transmembrane domain D3S1
Likely pathogenic (PS2, PM1, 
PM2, PP2) 
MPC = 2.37
None 8 mo M Initially normal (1 y- 3 y 
4 mo), then BG slowing 
(7- 10 y); 
postictal: abundant beta, 
diffusely slow BG
DD/MID SZ reduction: VPA, LEV, CLB; 
no effect: STP; 
SZ aggravation: OXC
Hypotonia, ataxia, paroxysmal 
dystonia
10 2 y c.3722A>G p.Tyr1241Cys pending 
transmembrane domain D3S2
VUS (PM1, PP2) 
MPC = 2.48
None 8 mo F, A Focal posterior bilateral 
EDs
NA/MID SZ- free: VGB VGB Paroxysmal dyskinesia
11 2 y 1 mo c.3953A>G p.Asn1318Ser de novo 
cytoplasmic linker D3S4/D3S5
Likely pathogenic (PS2, PM2, PP2) 
MPC = 2.04
None 3 mo F, GTC Normal; ictal: EDs on the 
P regions bilaterally
N/N SZ reduction: CBZ, PER; 
no effect: PB, OXC, CLB, ZNS; 
adverse effects: TPM 
(hyperthermia)
Ataxia
12 2 y 3 mo c.3956C>A p.Ala1319Asp de novo 
cytoplasmic linker D3S4/D3S5
Likely pathogenic (PS2, PM2, PP2) 
MPC = 2.69
None 2 mo C, T, GTC Normal; 
ictal EEG: parasagittal 
EDs, F rhythmic delta
N/MID SZ reduction: PHT; 
no effect: VPA, PB
Ataxia, tremor, language delay
13 7 y 11 mo c.3967G>A p.Ala1323Thr, de novo 
cytoplasmic domain D3S4/D3S5
Likely pathogenic (PS2, PM2, PP2) 
MPC = 2.22
None 5 mo FS, GTC Normal N/N SZ- free: VPA VPA
14 c.4391T>C p.Ile1464Thr paternal 
inactivation gate
Likely pathogenic (PM1, PM2, 
PP1, PP2) 
MPC = 2.65
See Figure 1 7 mo A, GTC, SE Diffuse abnormal NA/MID SZ reduction: TPM, VPA
15 10 y 6 m c.4423G>A p.Gly1475Arg, inactivation 
gate
Likely pathogenic (PS1, PM2, PP1, 
PP2) 
MPC = 1.54
See Figure 1 9 mo F to GTC, AA Slowing over the 
temporal region (3 y), 
then normal (9 y)
NA/MID SZ- free: LTG; 
SZ reduction: OXC, CBZ; 
no effect: LEV
LTG Hypotonia, ataxia, autistic 
features
16 9 mo c.4423G>A p.Gly1475Arg de novo, 
inactivation gate
Pathogenic (PS1, PS2, PP2) 
MPC = 1.54
None 4 mo F, T Ictal: slowing and EDs on 
both hemispheres, 
mainly temporal regions
NA/MID SZ- free: PHT; 
no effect: LEV
PHT Hypotonia, ataxia
17 9 y 9 mo c.4423G>A p.Gly1475Arg de novo 
blood mosaicism 10% inactivation 
gate
Pathogenic (PS1, PS2, PP2) 
MPC = 1.54
None 11 mo GTC, F Normal N/N SZ- free: CBZ; 
SZ reduction: VPA
CBZ
(Continues)
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guidelines, MPC Family history Age at SZ onset SZ types
Interictal EEG/ictal 
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Cognition before SZ 
onset/cognition after SZ 
onset Treatment response
Successful 
monotherapy Other features
18 8 y c.4447 G>A, p.Glu1483Lys de novo 
inactivation gate
Pathogenic (PS1, PS2, PS3, PM2, 
PP2) 
MPC = 2.13
None 11 mo F, GTC Normal background, 
small spikes/theta pointu 
in the central regions
N/N Sz- free: VPA, CBZ, currently no 
AED
Clumsy, shy, speech delay
19 2 y c.4585A>G p.Met1529Val de novo 
transmembrane D4S1
Likely pathogenic (PS2, PM1, 
PM2, PP2) MPC = 1.2
None 4 mo GTC Right posterior slow 
activity during sleep; 
ictal: generalized spike 
discharges
N/N No effect: LEV, PB, VPA
20 11 y c.4764C>G p.Phe1588Leu de novo 
transmembrane D4S3
Pathogenic (PS1, PS2, PM1, PM2, 
PP2) 
MPC = 2.4
None 3.5 mo GTC, AA, T, F Normal DD/MID SZ- free: CBZ CBZ Autism, language delay 
21 13 y c.4764C>A p.Phe1588Leu de novo 
transmembrane D4S3
Pathogenic (PS1, PS2, PM1, PM2, 
PP2) 
MPC = 2.4
None 5 mo F, GTC NA N/MID SZ reduction: PB, CBZ Obesity
22 2 y 8 mo c.4840A>G p.Thr1614Ala de novo 
extracellular domain D4S3/D4S4
Likely pathogenic (PS2, PM2, PP2) 
MPC = 2.17
None 4.5 mo AA, GTC, M, A Generalized SW N/MID SZ reduction: VPA, OXC
23 7 y 5 mo c.4850G>C p.Arg1617Gln de novo 
transmembrane D4S4
Pathogenic (PS1, PS2, PM1, PM2, 
PP2) 
MPC = 2.4
None 5 mo GTC Normal DD/MD SZ- free: LTG LTG Autism
24 9 y c.4850G>A p.Arg1617Gln de novo 
transmembrane D4S4
Pathogenic (PS1, PS2, PM1, PM2, 
PP2) 
MPC = 2.4
Paternal first cousin with 
microcephaly
5 mo GTC, M, A NA DD/MID Language delay, paroxysmal 
dyskinesia
25 24 y c.4850G>A p.Arg1617Gln de novo 
transmembrane D4S4
Pathogenic (PS1, PS2, PM1, PM2, 
PP2) 
MPC = 2.4
None NA GTC, F NA MID/MID SZ- free: CBZ, VPA Extrapyramidal signs
26 7 y c.4949 C>T p.Ala1650Val de novo 
cytoplasmic D4S4/D4S5
Pathogenic (PS1, PS2, PM2, PP2) 
MPC = 2.26
None 11 mo M, A, T, S, AA Generalized EDs NA/MID SZ- free: CLB, RUF, KD; adverse 
effects: LEV (increased 
frequency), ZNS (new SZ type), 
VPA (neurodevelopmental 
regression)
Hypotonia, supraventricular 
tachycardia
27 9 y c.4961T>A p.Ile1654Asn unknown 
transmembrane domain D4S5
Likely pathogenic (PM1, PM2, 
PP2) 
MPC = 2.92
None 2 y 8 mo Ab Generalized 3- Hz SW; 
spikes occipital right 
and left
NA/MID No effect: VPA Ataxia
28 4 y c.5273T>C p.Val1758Ala de novo 
transmembrane D4S6
Likely pathogenic (PS2, PM1, 
PM2, PP2) 
MPC = 2.46
None 2 y Ab, FS Mild BG slowing, 
irregular generalized 
EDs, OIRDA; 
ictal: irregularly 
generalized, 3- Hz SW 
followed by rhythmic 
diffuse delta activity 
(clinically: arrest of 
ongoing activity)
N/N SZ- free: ETX; no effect: LEV ETX
29 9 y c.5311G>A p.Val1771Ile de novo 
C- terminal
Likely pathogenic (PS2, PM2, PP2) 
MPC = 2.02
None 6 mo GTC, T Normal N/N SZ reduction: CBZ
30 6 y c.5458C>T p.Arg1820* de novo 
C- terminal
Pathogenic (PVS1, PS1, PM2, PP2) None 3- 4 mo M in hands and 
fingers
Trains of SW, right CP; 
irregular delta activity 
on the left side
NA/MID SZ reduction: LTG Ataxia, language delay
31 15 y c.5497G>C p.Asp1833His unknown 
C- terminal
Likely pathogenic (PM1, PM2, 
PP2) 
MPC = 2.44
None 6 mo T EDs over the posterior 
lobe
N/N SZ- free: PB; 
no effect: LEV
PB Reflux
32 3 y c.5597G>A, p.Arg1866Gln, de novo 
C- terminal
Likely pathogenic (PS2, PM2, PP2) 
MPC = 2.39
None 9 mo F, A, AA EDs, mid CP N/mild learning disability SZ- free: CBD; no effect: CBZ, 
CLB, LEV, TPM, VGB, VPA, 
ST; 
adverse effects: CBZ 
(drowsiness and severe 
cognitive disturbance)
CBD
33 c.5615G>A p.Arg1872Gln paternal 
(mosaic) cytoplasmic c- terminal
Likely pathogenic (PS1, PM2, PP1, 
PP2) 
MPC = 2.39
See Figure 1 6 wk F, clusters of GTC, 
SE
Normal N/N SZ- free: CBZ + LEV Learning difficulties
34 14 y c.5630A>G, p.Asn1877Ser, pending 
cytoplasmic c- terminal
Likely pathogenic (PS1, PM2, PP2) 
MPC = 2.04
None 5 mo F clustering Normal N/N SZ- free: LTG LTG Language delay
T A B L E  1  (Continued)
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Proband #
Age at 
inclusion Variant, inheritance, location
Pathogenicity per ACMG 
guidelines, MPC Family history Age at SZ onset SZ types
Interictal EEG/ictal 
EEG
Cognition before SZ 
onset/cognition after SZ 
onset Treatment response
Successful 
monotherapy Other features
18 8 y c.4447 G>A, p.Glu1483Lys de novo 
inactivation gate
Pathogenic (PS1, PS2, PS3, PM2, 
PP2) 
MPC = 2.13
None 11 mo F, GTC Normal background, 
small spikes/theta pointu 
in the central regions
N/N Sz- free: VPA, CBZ, currently no 
AED
Clumsy, shy, speech delay
19 2 y c.4585A>G p.Met1529Val de novo 
transmembrane D4S1
Likely pathogenic (PS2, PM1, 
PM2, PP2) MPC = 1.2
None 4 mo GTC Right posterior slow 
activity during sleep; 
ictal: generalized spike 
discharges
N/N No effect: LEV, PB, VPA
20 11 y c.4764C>G p.Phe1588Leu de novo 
transmembrane D4S3
Pathogenic (PS1, PS2, PM1, PM2, 
PP2) 
MPC = 2.4
None 3.5 mo GTC, AA, T, F Normal DD/MID SZ- free: CBZ CBZ Autism, language delay 
21 13 y c.4764C>A p.Phe1588Leu de novo 
transmembrane D4S3
Pathogenic (PS1, PS2, PM1, PM2, 
PP2) 
MPC = 2.4
None 5 mo F, GTC NA N/MID SZ reduction: PB, CBZ Obesity
22 2 y 8 mo c.4840A>G p.Thr1614Ala de novo 
extracellular domain D4S3/D4S4
Likely pathogenic (PS2, PM2, PP2) 
MPC = 2.17
None 4.5 mo AA, GTC, M, A Generalized SW N/MID SZ reduction: VPA, OXC
23 7 y 5 mo c.4850G>C p.Arg1617Gln de novo 
transmembrane D4S4
Pathogenic (PS1, PS2, PM1, PM2, 
PP2) 
MPC = 2.4
None 5 mo GTC Normal DD/MD SZ- free: LTG LTG Autism
24 9 y c.4850G>A p.Arg1617Gln de novo 
transmembrane D4S4
Pathogenic (PS1, PS2, PM1, PM2, 
PP2) 
MPC = 2.4
Paternal first cousin with 
microcephaly
5 mo GTC, M, A NA DD/MID Language delay, paroxysmal 
dyskinesia
25 24 y c.4850G>A p.Arg1617Gln de novo 
transmembrane D4S4
Pathogenic (PS1, PS2, PM1, PM2, 
PP2) 
MPC = 2.4
None NA GTC, F NA MID/MID SZ- free: CBZ, VPA Extrapyramidal signs
26 7 y c.4949 C>T p.Ala1650Val de novo 
cytoplasmic D4S4/D4S5
Pathogenic (PS1, PS2, PM2, PP2) 
MPC = 2.26
None 11 mo M, A, T, S, AA Generalized EDs NA/MID SZ- free: CLB, RUF, KD; adverse 
effects: LEV (increased 
frequency), ZNS (new SZ type), 
VPA (neurodevelopmental 
regression)
Hypotonia, supraventricular 
tachycardia
27 9 y c.4961T>A p.Ile1654Asn unknown 
transmembrane domain D4S5
Likely pathogenic (PM1, PM2, 
PP2) 
MPC = 2.92
None 2 y 8 mo Ab Generalized 3- Hz SW; 
spikes occipital right 
and left
NA/MID No effect: VPA Ataxia
28 4 y c.5273T>C p.Val1758Ala de novo 
transmembrane D4S6
Likely pathogenic (PS2, PM1, 
PM2, PP2) 
MPC = 2.46
None 2 y Ab, FS Mild BG slowing, 
irregular generalized 
EDs, OIRDA; 
ictal: irregularly 
generalized, 3- Hz SW 
followed by rhythmic 
diffuse delta activity 
(clinically: arrest of 
ongoing activity)
N/N SZ- free: ETX; no effect: LEV ETX
29 9 y c.5311G>A p.Val1771Ile de novo 
C- terminal
Likely pathogenic (PS2, PM2, PP2) 
MPC = 2.02
None 6 mo GTC, T Normal N/N SZ reduction: CBZ
30 6 y c.5458C>T p.Arg1820* de novo 
C- terminal
Pathogenic (PVS1, PS1, PM2, PP2) None 3- 4 mo M in hands and 
fingers
Trains of SW, right CP; 
irregular delta activity 
on the left side
NA/MID SZ reduction: LTG Ataxia, language delay
31 15 y c.5497G>C p.Asp1833His unknown 
C- terminal
Likely pathogenic (PM1, PM2, 
PP2) 
MPC = 2.44
None 6 mo T EDs over the posterior 
lobe
N/N SZ- free: PB; 
no effect: LEV
PB Reflux
32 3 y c.5597G>A, p.Arg1866Gln, de novo 
C- terminal
Likely pathogenic (PS2, PM2, PP2) 
MPC = 2.39
None 9 mo F, A, AA EDs, mid CP N/mild learning disability SZ- free: CBD; no effect: CBZ, 
CLB, LEV, TPM, VGB, VPA, 
ST; 
adverse effects: CBZ 
(drowsiness and severe 
cognitive disturbance)
CBD
33 c.5615G>A p.Arg1872Gln paternal 
(mosaic) cytoplasmic c- terminal
Likely pathogenic (PS1, PM2, PP1, 
PP2) 
MPC = 2.39
See Figure 1 6 wk F, clusters of GTC, 
SE
Normal N/N SZ- free: CBZ + LEV Learning difficulties
34 14 y c.5630A>G, p.Asn1877Ser, pending 
cytoplasmic c- terminal
Likely pathogenic (PS1, PM2, PP2) 
MPC = 2.04
None 5 mo F clustering Normal N/N SZ- free: LTG LTG Language delay
(Continues)
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1. The MPC score, which demonstrates a 5.8-fold increased 
variant enrichment in cases compared to individuals from 
the general population for MPC scores > 2.21
2. The paralog conservation score (parazscore), which quan-
tifies amino-acid position conservation across human pro-
teins of the same gene family. A significant enrichment of 
disease-associated missense variants was observed at par-
alog-conserved sites.22
3. The Grantham score, which accesses the effect of the 
amino acid substitution based on the properties of the 
amino acid exchange. It ranks amino acid substitutions 
from similar amino acids substitutions (0) to substitutions 
that differ in their chemical properties.23
4. The allele frequency analysis based on the alleleFrequen-
cyApp (see Web Resources), which calculates a maximum 
credible number of possible pathogenic alleles observed in 
gnomAD. The allele count is estimated based on the dis-
ease prevalence, the allelic and genetic heterogeneity, and 
the variant penetrance. For SCN8A, we specified the dis-
ease prevalence as one in 300, the allelic heterogeneity as 
0.01, the genetic heterogeneity as 0.1, and the penetrance as 
50%, resulting in a maximum number of a single allele in 
gnomAD. We compared the corresponding value with the 
allele frequency of variants present in gnomAD.
SCN8A- positive patients underwent a detailed clinical 
evaluation, and patients with severe DEE and BFIS were 
excluded from the study. The criteria for severe DEE were 
defined as severe, pharmacoresistant epilepsy, and devel-
opmental impairment, as previously reported.24 BFIS is a 
self- limiting epilepsy syndrome characterized by afebrile 
seizures, typically in clusters, with onset between 4 and 
8 months. Neurological examination, psychomotor devel-
opment, and the interictal electroencephalogram (EEG) are 
normal, and the children become seizure- free within the first 
years of life and sustain seizure freedom without the aid of 
antiepileptic drugs (AEDs).25
Additional probands were collected from an international 
network of epilepsy genetics clinics. Data on clinical pheno-
type, genetics, neuroimaging, and EEG were requested for all 
patients (and if possible, relatives) who were included in the 
study. Seizures were classified according to the International 
League Against Epilepsy.26 All probands, and in the case of 
minors, legal parents, provided written informed consent. 
The study was approved by the local ethical committees.
Sodium channel blockers (SCBs) were defined as AEDs 
that target sodium channels and included carbamazepine 
(CBZ), oxcarbazepine, lamotrigine (LTG), and phenytoin 
(PHT).
2.1 | Data sharing
Anonymized data will be shared by request from any quali-
fied investigator.
3 |  RESULTS
By the use of targeted NGS screening of SCN8A in a cohort 
of 1095 patients, we identified 12 (1.2%) probands with a 
predicted pathogenic variant in SCN8A. Six of the patients 
fulfilled the criteria for a severe DEE and thus were ex-
cluded from this study. Of the 1095 patients screened, ap-
proximately 326 fulfilled a DEE diagnosis (this might be an 
underestimate, as referrals to our center are often lacking 
clinical information). In addition to the remaining six pa-
tients, we ascertained 30 additional probands/families with 
predicted pathogenic SCN8A variants through collaborat-
ing diagnostic and research laboratories. The Asn1877Ser 
variant was seen in three controls in gnomAD, but as the 
Proband #
Age at 
inclusion Variant, inheritance, location
Pathogenicity per ACMG 
guidelines, MPC Family history Age at SZ onset SZ types
Interictal EEG/ictal 
EEG
Cognition before SZ 
onset/cognition after SZ 
onset Treatment response
Successful 
monotherapy Other features
35 4 y 4 mo c.5630A>G Asn1877Ser paternal 
cytoplasmic c- terminal
Likely pathogenic (PS1, PM2, PP1, 
PP2) 
MPC = 2.04
See Figure 1 6 mo Normal N/MID SZ- free: LTG, VPA
36 4 y 6 mo c.5630A>G p.Asn1877Ser unknown 
cytoplasmic c- terminal
Likely pathogenic (PS1, PM2, PP2) 
MPC = 2.04
None 7 mo GTC, T, AA Sporadic EDs, FC 
bilateral > right
N/MID SZ reduction: VPA, PB, TPM Ataxia, clumsiness
A, atonic; AA, atypical absences; Ab, absences; ACMG, American College of Medical Genetics and Genomics; ADHD, attention- deficit/hyperactivity disorder; AED,  
antiepileptic drug; AMD, amantadine; BG, background; C, clonic; CBD, cannabidiol; CBZ, carbamazepine; CLB, clobazam; CLZ, clonazepam; CP, cerebral paresis;  
DD, developmental delay; ED, epileptiform discharges; EEG, electroencephalogram; ESM, ethosuximide; ETX, ethosuximide; F, focal; FC, focal clonic; FS, febrile seizures;  
GTC, generalized tonic– clonic; ID, intellectual disability; KD, ketogenic diet; LEV, levetiracetam; LTG, lamotrigine; LZP, lorazepam; M, myoclonic; MD, moderate  
intellectual disability; MID, mild intellectual disability; MPC, missense badness, PolyPhen- 2, and constraint; N, normal; NA, not available; O, occipital; OIRDA, occipital  
intermittent rhythmic delta activity; OXC, oxcarbazepine; P, parietal; PB, phenobarbital; PER, perampanel; PHT, phenytoin; PP1, pathogenicity possible 1; PP2,  
pathogenicity possible 2; PP3, pathogenicity possible 2; PS1, pathogenicity strong 1; PS2, pathogenicity strong 2; PS3, pathogenicity strong 3; PVS1, pathogenicity very  
strong 1; RFM, rufinamide; RUF, rufinamide; S, spasms; SE, status epilepticus; STP, stiripentol; SW, spike and wave complexes; SZ, seizure(s); T, tonic; TPM, topiramate;  
UTR, untranslated region; VGB, vigabatrin; VPA, valproic acid; VUS, variant of unknown significance; ZNS, zonisamide.
T A B L E  1  (Continued)
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phenotype resembles a benign familial epilepsy, with several 
family members affected, and was seen in three probands in 
this study, it was included as being pathogenic. All variants, 
except #10 p.Tyr1241Cys, were classified as pathogenic or 
likely pathogenic according to the ACMG criteria.20 Not 
all missense variants in SCN8A are pathogenic, and at 384 
amino acid positions variants have been reported in the gen-
eral population.27
Distinguishing disease- causing variants from benign vari-
ants is still a challenge in clinical genetics. Rarity of an allele 
is widely recognized as a necessary (although not sufficient) 
criterion for variant pathogenicity (ACMG guidelines, but 
the key question “how common is too common?” remains 
poorly answered for many diseases).20 Estimating the genetic 
and allelic heterogeneity offers an opportunity to identify 
variant cutoff frequency filters. Genetic heterogeneity is the 
maximum proportion of disease that is attributable to varia-
tion in a single gene, and allelic heterogeneity is the maxi-
mum proportion of variation within a gene that is attributable 
to a single allele.
The patient variant 10 (c.3722A>G, p.Tyr1241Cys, 
NM_014191.3) was found once in the gnomAD27 and dis-
covEHR28 database. The presence of a variant in databases 
does not represent a pathogenicity exclusion criterion based 
on our allele frequency analysis for mild forms of epilepsy. 
The amino acid residue position is relatively conserved 
across voltage- gated sodium channels (positive parazscore = 
0.2322). In addition, the MPC score (MPC = 2.48) supports 
variant pathogenicity and the Grantham score of 194 indi-
cates a likely pathogenic variant.
One of the probands (#30) has previously been mentioned 
briefly,29 but was included in this study because additional 
data had been collected.
In total, 36 probands/families were included. The detected 
SCN8A variants were mainly missense variants (33/36) 
scattered throughout the gene. In addition, two truncating 
variants (one frameshift [#4] and one stop [#30]), and one 
variant causing a nucleotide change eight base pairs upstream 
of the start codon (#1) were detected. Fourteen variants were 
located in the transmembrane domains and two in the pore- 
forming domain; of the cytoplasmic variants, we found one in 
the D1/D2 domain. The variant Asn544 fs* was a frameshift 
variant with a clinical picture of absence epilepsy, inherited 
from an affected parent, and classified as pathogenic accord-
ing to the ACMG classification guidelines.
The variants either occurred de novo or segregated within 
the family in a dominant fashion (#2, #4, #7, #14, #15, #33, 
and #34; see Figure 1 for selected pedigrees). In the family 
of Proband #33, the variant was inherited from an affected 
mosaic parent. Mosaicism was also suspected in #15, but has 
not yet been confirmed. All variants were located at highly 
conserved residues and were predicted to be possibly dam-
aging according to computational prediction software (see 
Materials and Methods and Web Resources). Mining the 
available literature and databases, nine variants were found to 
be recurrent either within this study or overall; Ile763Val,30 
Val891Met,31 Gly1475Arg,10,32 Gly1483Lys,17 Phe1588Leu, 
Arg1617Gln,5,7,8,33,34 Ala1650Val5,7,35 (different amino acid 
substitution, see Discussion section), Arg1872Gln7,12,36 and 
Asn1877Ser,30,35,37 with five of them (amino acid positions 
763, 1475, 1617,1650, and 1872) seen in severe DEE pheno-
types as well.
Clinical data on all 36 probands and families are presented 
in Table 1. Age at inclusion varied from 9 months to 35 years, 
with a mean of 7.9 years. Seizure onset was between 6 weeks 
and 7 years, with a mean of 13.6 months (SD = ±17 months). 
Seizure semiology was very diverse, and included gener-
alized tonic– clonic (n = 21), focal (n = 14), tonic (n = 8), 
myoclonic (n = 6), and atonic seizures (n = 8), as well as 
epileptic spasms (n = 2) and atypical/typical absences (n = 
Proband #
Age at 
inclusion Variant, inheritance, location
Pathogenicity per ACMG 
guidelines, MPC Family history Age at SZ onset SZ types
Interictal EEG/ictal 
EEG
Cognition before SZ 
onset/cognition after SZ 
onset Treatment response
Successful 
monotherapy Other features
35 4 y 4 mo c.5630A>G Asn1877Ser paternal 
cytoplasmic c- terminal
Likely pathogenic (PS1, PM2, PP1, 
PP2) 
MPC = 2.04
See Figure 1 6 mo Normal N/MID SZ- free: LTG, VPA
36 4 y 6 mo c.5630A>G p.Asn1877Ser unknown 
cytoplasmic c- terminal
Likely pathogenic (PS1, PM2, PP2) 
MPC = 2.04
None 7 mo GTC, T, AA Sporadic EDs, FC 
bilateral > right
N/MID SZ reduction: VPA, PB, TPM Ataxia, clumsiness
A, atonic; AA, atypical absences; Ab, absences; ACMG, American College of Medical Genetics and Genomics; ADHD, attention- deficit/hyperactivity disorder; AED,  
antiepileptic drug; AMD, amantadine; BG, background; C, clonic; CBD, cannabidiol; CBZ, carbamazepine; CLB, clobazam; CLZ, clonazepam; CP, cerebral paresis;  
DD, developmental delay; ED, epileptiform discharges; EEG, electroencephalogram; ESM, ethosuximide; ETX, ethosuximide; F, focal; FC, focal clonic; FS, febrile seizures;  
GTC, generalized tonic– clonic; ID, intellectual disability; KD, ketogenic diet; LEV, levetiracetam; LTG, lamotrigine; LZP, lorazepam; M, myoclonic; MD, moderate  
intellectual disability; MID, mild intellectual disability; MPC, missense badness, PolyPhen- 2, and constraint; N, normal; NA, not available; O, occipital; OIRDA, occipital  
intermittent rhythmic delta activity; OXC, oxcarbazepine; P, parietal; PB, phenobarbital; PER, perampanel; PHT, phenytoin; PP1, pathogenicity possible 1; PP2,  
pathogenicity possible 2; PP3, pathogenicity possible 2; PS1, pathogenicity strong 1; PS2, pathogenicity strong 2; PS3, pathogenicity strong 3; PVS1, pathogenicity very  
strong 1; RFM, rufinamide; RUF, rufinamide; S, spasms; SE, status epilepticus; STP, stiripentol; SW, spike and wave complexes; SZ, seizure(s); T, tonic; TPM, topiramate;  
UTR, untranslated region; VGB, vigabatrin; VPA, valproic acid; VUS, variant of unknown significance; ZNS, zonisamide.
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12). Seizure severity did not progress over time, and seizure 
triggers were not found. Three probands experienced convul-
sive status epilepticus (#3, #14, #33).
The interictal EEG was available in 33 of 36 patients and 
showed focal epileptiform abnormalities in 15 patients (45%), 
predominant in the posterior quadrants in (10 patients) or in 
the central/centroparietal/frontocentral regions (five patients), 
with or without bilateral spreading. Four patients (12%) had 
only generalized abnormalities (#6, #14, #22, #26). In 12 pa-
tients (39%), the interictal EEG was normal (#9, #11, #12, #13, 
#16, #17, #20, #23, #29, #34, #35) or normalized at follow- up 
(#15). Ictal EEG was available in four patients, showing a focal 
discharge in two (#6, #11) and generalized spike or irregular 
spike and waves discharges in the other two (#19, #28).
F I G U R E  1  Pedigrees of SCN8A- 
related epilepsies showing segregation of the 
variant with the phenotype. ID, intellectual 
disability
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Cognitively, these patients fare well. Before seizure onset, 
26 of 36 (72%) had normal cognitive development, two of 
36 (6%) had a mild ID, one of 36 had moderate ID (3%), and 
four of 36 (11%) had developmental delay, not classified due 
to the young age of the patient. At follow- up, a deteriora-
tion from normal intellect/developmental delay to mild ID or 
from mild ID/developmental delay to moderate ID was seen 
in seven (19%) patients, whereas 81% did not experience de-
terioration after seizure onset. At the time of follow- up, 22 of 
36 (61%) had mild ID and two of 36 (6%) had moderate ID.
Additional features included ataxia (10/36), hypoto-
nia (7/36), language delay (5/36), autism/autistic features 
(4/36), movement disorders (3/36) including paroxysmal 
dyskinesia (3/36), gait disturbances (2/36), sleep distur-
bances (1/36), learning difficulties (2/36), and attention- 
deficit/hyperactivity disorder (1/36). See Table 1 for 
details.
All probands were evaluated for their treatment re-
sponse. Twenty- one of 36 (58%) probands became seizure- 
free. Monotherapy was sufficient in 12 of 21 (57%) 
probands, and included LTG (n = 3), CBZ (n = 2), PHT 
(n = 1), valproate (n = 2), vigabatrin (n = 1), ethosuxim-
ide (n = 1), phenobarbital (n = 1), and levetiracetam (n = 
1). In total, 13 of 36 (36%) probands became seizure- free 
with therapy that included an SCB either in monotherapy 
or in combination with other AEDs. One became seizure- 
free with a small dose of cannabidiol. However, seven of 
36 (19%) probands became seizure- free without the use of 
SCBs. Seizure offset was only available for six patients, 
and ranged between 4 and 10 years; mean age at seizure 
offset was 7.7 years.
Six probands had affected family members, segregating 
with the variants. For Proband #5, a similar phenotype with 
absences and learning/language difficulties was seen in the 
sister, as well as the mother. For Proband #7, the mother also 
had unspecified epilepsy and carried the variant; there was 
also an affected maternal grandfather, who did not have ge-
netic analysis done. Likewise, Proband #14 had an affected 
father, who carried the variant, and an affected paternal 
grandfather, who was not tested genetically. Proband #15 
had a sister with a similar epilepsy phenotype; the variant 
was suspected to have been inherited from a mosaic parent, 
but this was not confirmed at the time of preparation of this 
paper. Proband #33 had an affected sister with a similar phe-
notype, and genetic investigations showed that the variant 
was inherited from an affected mosaic (28%) father. Proband 
#34 had an affected sister and mother, in whom the variant 
segregated.
4 |  DISCUSSION
Pathogenic variants in SCN8A have so far been described 
in patients with different epilepsy phenotypes, including 
rare families with BFIS and in >100 patients with mild 
to severe DEE. In this study, we describe the electroclini-
cal phenotype of 36 patients with intermediate epilep-
sies due to pathogenic variants in SCN8A. Patients with 
F I G U R E  2  A partial display of published variants, with the recurrent developmental and epileptic encephalopathy (DEE) and known loss- 
of- function variants, as well as those identified in this study. Blue indicates intellectual disability or ataxia without epilepsy.44,47 Green indicates 
intermediate epilepsy (this study). Red indicates DEE variants (previously published4,7,24). Pink indicates recurrent variants: DEE and intermediate 
epilepsy
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SCN8A- related severe DEE21 and BFIS18 were excluded 
from the study.
The variant at position c.- 8A>G was assumed to be likely 
pathogenic because it occurred de novo and the clinical fea-
tures of the patient resembled the phenotype seen in other 
SCN8A patients. The variant is located outside of the Kozak 
consensus sequence, but may lead to increased RNA stability 
or translational initiation or result in altered splicing pattern. 
These theories can only be confirmed by functional testing 
of the variant, which unfortunately was not possible in this 
study. Until then, the variant may need to be classified as a 
variant of unknown significance.
All 36 patients presented with seizures in early child-
hood (mean = 13.6 months). Before seizure onset, 72% 
probands had normal cognitive development. More than 
half of the probands became seizure- free, 57% of these 
with monotherapy. Compared to the BFIS families, de-
scribed by Gardella et al,17 Anand et al,37 and Han et al,18 
the majority of the probands in this cohort have cognitive 
impairment, with 6% suffering from moderate ID and 61% 
from mild ID. Furthermore, only 58% became seizure- free 
compared to almost 100% of the BFIS patients; seizure 
freedom is exceptional in the severe DEE phenotype. The 
patients herein described also appeared to have additional 
neurological disturbances, including primarily ataxia (in 
28%) and hypotonia (in 19%). In the severe DEE cohort, 
the incidence of ataxia is around 11%, compared to the 
28% of this cohort. However, it is important to note that 
many of the patients suffering from severe SCN8A DEE 
are unable to walk autonomously. Furthermore, the patients 
in this intermediate cohort do not suffer from the spastic-
ity and paraplegia or the extrapyramidal/cerebellar symp-
toms that up to 50% of the severe DEE patients do.24 A 
few patients in this cohort (8%) had dyskinesia, which is 
also seen in both severe DEEs and BFIS families. Growth 
impairment (microcephaly or reduced growth), observed in 
severe DEE, was not seen in this cohort. Other prominent 
phenotypic features included language delay/difficulties in 
14% and movement disorders not further specified in 8%.
In mouse models, it has been shown that SCN8A is 
widely expressed, both in the motor neurons of the brain-
stem and in many types of neurons in the cerebellum, where 
functional deficits in Purkinje cells have been found,38–40 
confirming the importance of SCN8A in motor function. 
This could explain the involvement of the motor system, 
and why cerebellar atrophy and ataxia,41 associated with 
intellectual impairment, appeared to be major features in 
subjects harboring SCN8A variants. The cerebellum does, 
however, also play an important role in language and gram-
mar processing, verbal working memory, and speech motor 
planning,42 and a large proportion of SCN8A patients, 
 including those reported in the present cohort, show an 
 impairment of these functions as well.
When comparing the present cohort to the severe SCN8A 
DEE population, in which patients have earlier seizure onset, 
with more pronounced cognitive deficits as well as refractory 
epilepsy, we tried to identify possible predictive factors that 
in newly diagnosed patients could help to detect those with a 
milder course as compared to those with a more severe evo-
lution. First, within our cohort, the majority of probands have 
normal development prior to seizure onset (and 33% of them 
continue to develop normally) and maintain a normal EEG 
(41%). This is often not the case in probands who develop 
severe DEE, in which the majority usually are cognitively de-
layed from birth,43 or will present with cognitive difficulties 
early on and show changes in their EEGs. However, it is not 
an absolute feature, as we have observed several children with 
an extremely severe condition at follow- up, despite early nor-
mal development. Second, seizure onset occurred at a mean 
age of 13.6 months, compared to a mean age of 4 months in 
the DEE group.43 It is worth bearing in mind that the age 
deviation in this cohort is quite large (SD = ±17 months), 
and thus, these numbers should be interpreted carefully when 
counseling a family. Last, seizure freedom was obtained in 
58% of the patients in this cohort, and it was achieved rap-
idly and with monotherapy in two- thirds. In contrast, only 
about 5% of patients in the severe DEE cohort achieve seizure 
freedom with monotherapy. This is important, albeit also a 
prerequisite in this study, where the more severe epilepsies 
were excluded.
Previously, it has been hypothesized that seizures in pa-
tients with SCN8A variants should respond to SCBs.16,17 A 
beneficial effect of SCBs was observed in 36% of the patients 
reported in this study, either as monotherapy or in combina-
tion with other AEDs, and supportive of this, previous studies 
have shown a GOF of the Arg1617Gln and Arg1872Leu12 
variants. However, 19% became seizure- free without the 
use of SCBs, suggesting that seizure freedom should not be 
F I G U R E  3  The spectrum of SCN8A- 
related epilepsy. DEE, developmental and 
epileptic encephalopathy; ID, intellectual 
disability; SUDEP, sudden unexpected death 
in epilepsy
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attributed solely to the use of SCBs, but also should be con-
sidered a phenotypic trait.
Interestingly, a partial benefit of LTG was also observed 
in the proband with a stop variant (#30). We can speculate 
that this unexpected finding may depend on genetic modifiers 
and differences in genetic background, or may be because as 
the stop- codon is located at the c- terminal part of the protein, 
the transcript does not undergo nonsense- mediated decay.
Furthermore, we found three variants, one eight base pairs 
upstream of the start codon (#1), one frameshift variant (#4), 
and one stop variant (#30), all suspected to be LOF and all as-
sociated with an epilepsy phenotype. Previously, it has been 
hypothesized that LOF variants would not cause epilepsy,44 
but rather present with ID with or without motor function 
abnormalities, such as ataxia.2,34,41 However, Blanchard et al 
also describe a patient with epilepsy and ID, carrying an LOF 
variant,11 and two existing Scn8a knockout mice models sup-
port the notion of epilepsy also being a feature of LOF of 
NaV1.6.45,46 Other ion channel genes including SCN2A have 
been shown to have a similar clinical picture, where both 
GOF and LOF variants may cause epilepsy. The underlying 
functional causes are yet to be fully elucidated.
Variants were found throughout the gene (see Figure 2), in-
cluding the transmembrane segments, cytoplasmic loops, and 
inactivation gate, and thus, location in the gene is likely not 
predictable of functional or clinical effects of the variant; how-
ever, the figure does display that the majority of the variants 
are found in domains three and four, the inactivation gate and 
the c- terminal, which may help guide variant interpretation.
We identified several recurrent variants and observed 
a wide range of phenotypic variability for variant carriers. 
Ile763Val, Gly1475Arg, Arg1617Gln, Ala1650Val, and 
Arg1872Gln were all seen in this study, as well as in patients 
with DEE. Ile763Val has previously been described in a pa-
tient with intractable epilepsy and moderate ID,30 whereas 
we found it in two patients with focal epilepsy and mild ID 
(#5 and #6).
The Gly1475Arg variant is even more diverse, and it has 
previously been identified in several patients, including a 
child with severe DEE, who died from probable sudden unex-
pected death in epilepsy.10,32 In this cohort, we found it in two 
patients with mild ID, and epilepsy was controlled by SCBs. 
Both patients did suffer from hypotonia and ataxia.
Arg1617Gln has been seen in several DEE patients pre-
viously, including a girl with severe DEE who died after ter-
minal progression of her disease,2,17 whereas we found it in 
two patients with mild ID and treatable epilepsy (#24, #25). 
However, they did display additional neurological distur-
bances (language delay, dyskinesia) and their seizure onset 
was earlier (4 months), compared to the rest of this cohort. 
We also found the Arg1617Gln variant in one patient (#21), 
who displayed moderate ID as well as autism. Ala1650Val 
variant has not been described before (#26), but has been 
seen several times with a threonine (Ala1650Thr) substitu-
tion in patients with severe DEE.5,7,35 Arg1872Gln has also 
been seen several times in patients with severe DEE7,36; how-
ever, we found it in a sib pair, with normal intellect and focal 
epilepsy (#34). The Gly1483Lys variant has previously been 
described in BFIS17; the patient in this study (#18) carrying 
this variant has a very mild phenotype, with only speech 
delay, sporadic seizures, and discrete focal EEG abnormali-
ties. Why some variants show phenotypic heterogeneity and 
other variants do not remains elusive. Of course, differences 
in the amino acid substitution might explain some of the dif-
ference, but this is true for just a few of the variants. In other 
cases, genetic modifiers and differences in the genetic back-
ground could underlie these observations. Further studies are 
needed to investigate this further.
In conclusion, in this study we provide further insight 
into the phenotypic spectrum of SCN8A epilepsy by focus-
ing on an intermediate phenotype characterized by treatable 
epilepsy with a later age of onset, mildly impaired cognitive 
development, and variable but in general mild neurological 
disturbances. A positive response to epilepsy treatment, es-
pecially with SCBs, was observed. Even if a wide range of 
phenotypes related to SCN8A variants can be expected (see 
illustration in Figure 3), these findings highlight the presence 
of an increasing number of SCN8A patients with a phenotype 
of moderate severity.
The partial overlapping of genetic and early clinical fea-
tures in SCN8A- related epilepsies makes it difficult to provide 
proper counseling in these children so far. Further investiga-
tions are warranted to clarify this issue, as well as to explore 
possible prognostic factors.
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